Ipenoxazone (MLV-6976)
(Synonyms: 伊培沙宗; MLV-6976; NC-1200) 目录号 : GC31181
Ipenoxazone (MLV-6769) 是一种强效和中枢作用的肌肉松弛剂。
Cas No.:104454-71-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ipenoxazone is a potent and centrally acting muscle relaxant.
Ipenoxazone is a potent and centrally acting muscle relaxant[1]. An intravenous injection of 2 mg/kg Ipenoxazone causes a reduction of electromyographic activity which reaches a maximum within 3 min after the injection. Within 1 min after the injection of Ipenoxazone at a dose of 4 mg/kg, the blood pressure changes from a control level of 138±9 mmHg to a minimum level of 98±9 mmHg (n=6) but it rapidly returns to the control level within 1 to 2 min, while the rigidity is still reduced significantly at that time. High doses (greater than 30 mg/kg i.p.) of Ipenoxazone produces a transient and dose-dependent sedation in almost all mice about 5 min after its administration[2].
[1]. Kimura A, et al. Inhibitory effects of a new, potent, centrally acting muscle relaxant, (4S,5R)-4-(2-methylpropyl)-3-[3-(perhydroazepin-1-yl)propyl]-5- phenyl-1,3-oxazolidin-2-one (NC-1200) on micturition contractions of the bladder in rats. Eur J Pharmacol. 1988 Jul 26;152(1-2):55-62. [2]. Masaki M, et al. A new class of potent centrally acting muscle relaxants: pharmacology of oxazolidinones in rat decerebrate rigidity. Br J Pharmacol. 1986 Sep;89(1):219-28.
Animal experiment: | Experiments are performed on 31 adult male rats (Wistar 310 to 430 g, 3 to 7 months of age) anesthetized with chloralose-urethane (50 and 500 mg/kg i.p., respectively). Ipenoxazone is administrated i.v. at 0.05 to 0.1 mL/100 g body weight (20 to 40 s per injection). These four different doses of Ipenoxazone (0.3, 1, 3 and 10 mg/kg) are administrated cumulatively, from small doses to larger doses. It is usually waited about 10 to 30 min between each trial or until all effects of the drug on the bladder have disappeared[1]. |
References: [1]. Kimura A, et al. Inhibitory effects of a new, potent, centrally acting muscle relaxant, (4S,5R)-4-(2-methylpropyl)-3-[3-(perhydroazepin-1-yl)propyl]-5- phenyl-1,3-oxazolidin-2-one (NC-1200) on micturition contractions of the bladder in rats. Eur J Pharmacol. 1988 Jul 26;152(1-2):55-62. | |
| Cas No. | 104454-71-9 | SDF | |
| 别名 | 伊培沙宗; MLV-6976; NC-1200 | ||
| Canonical SMILES | O=C1O[C@H](C2=CC=CC=C2)[C@H](CC(C)C)N1CCCN3CCCCCC3 | ||
| 分子式 | C22H34N2O2 | 分子量 | 358.52 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7892 mL | 13.9462 mL | 27.8924 mL |
| 5 mM | 0.5578 mL | 2.7892 mL | 5.5785 mL |
| 10 mM | 0.2789 mL | 1.3946 mL | 2.7892 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet